While FDA approved far fewer new drugs in 2016 than 2015, the agency quickly approved novel and breakthrough therapies.
The US growth rate for spending on medicines is expected to fall in 2016 and beyond, according to new research.
Two new major studies on a biosimilar to trastuzumab (Herceptin, Genentech) to treat HER2-positive metastatic breast cancer and HER2-positive gastric cancer demonstrated equivalency.
CLINICAL

Event Resources

 

Stay current on the latest developments in your specialty with ModernMedicine's regularly updated collection of conference briefs and webinars.